迪瑞醫療(300396.SZ)獲得4項醫療器械註冊證
格隆匯3月7日丨迪瑞醫療(300396.SZ)公佈,公司於近日取得由國家藥監局頒發的4項《醫療器械註冊證》。產品名稱分別為“乙型肝炎病毒e抗體檢測試劑盒(化學發光免疫分析法)”、“乙型肝炎病毒核心抗體測定試劑盒(化學發光免疫分析法)”、“乙型肝炎病毒表面抗體測定試劑盒(化學發光免疫分析法)”、“總前列腺特異性抗原測定試劑盒(化學發光免疫分析法)”;註冊分類均為Ⅲ類。
上述《醫療器械註冊證》涉及化學發光免疫分析領域,延續註冊已獲得批准,有效期按照證書規定執行。上述產品的取得,延續了公司產品種類,將進一步增強公司產品的綜合競爭力,有利於進一步提高公司的市場拓展能力,對公司未來的經營將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.